If you've been researching tirzepatide and feeling confused about why there appear to be two different products — Zepbound and Mounjaro — you're not alone. The short answer is that they're the same medication with different brand names, approved for different conditions. The long answer involves FDA approval strategy, insurance coverage implications, and pricing dynamics that have real practical effects on which product you can access and at what cost.
The One-Sentence Answer
Zepbound and Mounjaro are both tirzepatide — the same active ingredient, the same doses, the same manufacturer (Eli Lilly). The only difference is what the FDA has approved them for: Mounjaro for type 2 diabetes, Zepbound for obesity and weight management.
A Quick Comparison
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA approval | Type 2 diabetes (May 2022) | Chronic weight management (Nov 2023) |
| Approved for | Adults with T2D | Adults with BMI ≥30, or ≥27 with weight-related condition |
| Doses available | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Delivery | Weekly subcutaneous injection (autoinjector pen) | Weekly subcutaneous injection (autoinjector pen) |
| Brand list price (monthly) | ~$1,000–$1,100 | ~$1,060–$1,100 |
| Insurance coverage | Often covered for T2D diagnosis | Often excluded from commercial insurance |
| Telehealth availability | Available | Available |
Why Two Brand Names for the Same Drug?
This is a common FDA strategy for medications with multiple therapeutic applications. A drug manufacturer submits separate New Drug Applications (NDAs) or supplemental applications for each indication, producing separate approval pathways — and in many cases, separate commercial brands.
The strategy serves several purposes:
- Regulatory clarity. Each approval is supported by its own clinical trial program. Mounjaro's approval was supported by the SURPASS trial program (T2D trials); Zepbound's was supported by the SURMOUNT trial program (obesity trials).
- Prescribing and coding clarity. Physicians can prescribe the product with the indication that matches their patient's diagnosis, which matters for insurance reimbursement.
- Market differentiation. Separate brands can be marketed separately to different prescriber audiences (endocrinologists vs. obesity medicine specialists) and priced differently over time.
The parallel isn't unique to Eli Lilly — Novo Nordisk does the same thing with semaglutide: Ozempic (diabetes) and Wegovy (obesity) are the same molecule at different doses. See our Ozempic vs Mounjaro comparison for more on the semaglutide family.
The Insurance Coverage Gap
This is where the Zepbound vs. Mounjaro distinction has the most practical impact.
Mounjaro (the diabetes brand) is often covered by commercial insurance plans for patients with a type 2 diabetes diagnosis. The FDA approval and established diabetes billing codes make coverage more predictable.
Zepbound (the obesity brand) faces a significantly more difficult insurance landscape. Most commercial insurance plans in the U.S. still exclude coverage for obesity medications — a coverage gap that exists largely for historical reasons rather than evidence-based reasons. Medicare Part D, until recently, was legally prohibited from covering weight-management medications (this began changing with the Inflation Reduction Act and subsequent CMS guidance).
The practical implication: A patient with type 2 diabetes who is prescribed Mounjaro may pay significantly less out of pocket than a patient with obesity and no diabetes diagnosis prescribed Zepbound, even though the medication is identical.
Some prescribers have navigated this by prescribing Mounjaro off-label for patients with pre-diabetes or metabolic syndrome, but this approach depends on the specific insurance plan and diagnosis coding — and is becoming more scrutinized.
Pricing: Brand vs. Compounded
Both Zepbound and Mounjaro carry brand-name list prices of approximately $1,000–$1,100 per month without insurance. The actual out-of-pocket cost depends on:
- Insurance coverage — see above; Mounjaro coverage for T2D diagnosis is substantially better
- Manufacturer savings cards — Eli Lilly has offered savings programs that historically reduced Mounjaro monthly cost significantly for commercially insured patients; check current program availability
- Specialty pharmacy pricing — some specialty pharmacies offer negotiated rates
- Compounded tirzepatide — the most significant cost difference
Compounded Tirzepatide: The Third Option
When brand-name tirzepatide was on the FDA shortage list, compounding pharmacies were authorized to produce tirzepatide for individual patient prescriptions. This produced a third option — compounded tirzepatide — available through telehealth platforms at substantially lower cost, typically $150–$450/month depending on provider and dose.
Compounded tirzepatide is neither Zepbound nor Mounjaro — it's the active ingredient tirzepatide prepared by a compounding pharmacy under a valid prescription. Patients who cannot afford brand-name products and whose insurance doesn't cover either brand have primarily accessed tirzepatide this way.
The regulatory status of compounded tirzepatide has evolved as shortage designations have changed. Check our compounding status tracker for the current regulatory picture before pursuing this option.
Which Is Available Through Telehealth?
Both Zepbound and Mounjaro are technically available through telehealth providers, subject to prescriber discretion and state availability. In practice, telehealth platforms that offer tirzepatide have historically been more likely to prescribe:
- Compounded tirzepatide (most common, lowest cost)
- Zepbound (available through select telehealth platforms for obesity-indication prescribing)
- Mounjaro (less commonly offered through telehealth for off-label weight management)
The specific product a telehealth provider can offer depends on their prescribing policies, state regulations, and pharmacy partnerships. Use our GLP-1 provider comparison to see which platforms offer tirzepatide and at what price.
For detailed pricing data across providers in your state, the tirzepatide cost guide covers current market pricing for both brand and compounded options.
Does It Matter Which Form You Take?
From a pharmacological standpoint: no. Tirzepatide is tirzepatide regardless of whether the box says Zepbound, Mounjaro, or compounded. The active molecule, dose, and mechanism are identical.
From a practical standpoint, the differences that matter are:
- Cost/insurance — potentially large difference depending on your coverage
- Regulatory status (for compounded options) — important to verify before starting
- Documentation — your medical record should reflect the product and indication correctly for insurance billing purposes
Weight Loss Efficacy: What the Trials Show
Because Mounjaro and Zepbound are the same drug, the weight loss data applies to both. Key numbers:
SURMOUNT-1 (obesity trial, Zepbound-indication data):
- Average weight loss: 20.9% body weight at tirzepatide 15mg over 72 weeks vs. 3.1% for placebo
- 63% of patients on 15mg achieved at least 20% weight loss
SURPASS-2 (diabetes trial, Mounjaro-indication data vs. semaglutide):
- Tirzepatide outperformed semaglutide at all doses for both A1C reduction and weight loss
SURMOUNT-5 (head-to-head vs. semaglutide for obesity):
- Tirzepatide 15mg: 20.2% weight loss vs. 13.7% for Wegovy (semaglutide 2.4mg) over 72 weeks
- 31.6% vs. 16.1% achieved ≥25% weight loss
These results apply regardless of which brand label is on the pen.
FAQ
If I'm already on Mounjaro for diabetes, is Zepbound "better" for weight loss?
No — they're the same drug. If you're on Mounjaro and achieving good glycemic control and weight loss results, there is no pharmacological reason to switch to Zepbound. The only scenarios where switching makes sense are administrative: if Zepbound is covered by your insurance and Mounjaro is not for your specific situation, or if your prescriber recommends it for other reasons.
Can I switch between Mounjaro and Zepbound doses seamlessly?
Yes. Because the medications are identical in formulation, switching between brands at the same dose requires no washout or re-titration. It's equivalent to changing pharmacies or filling the same prescription from a different manufacturer.
Does Zepbound have different side effects than Mounjaro?
No. The side effect profile is identical because the active ingredient is identical. The most common side effects — nausea, diarrhea, vomiting, constipation, and decreased appetite — are characteristic of tirzepatide at any dose, regardless of brand. Refer to our GLP-1 side effects management guide for strategies that apply to both products.
Which is harder to get right now — Zepbound or Mounjaro?
Supply availability varies by region and time. Historically, both have experienced shortage periods. Brand-name availability at your local pharmacy depends on supply chain and your specific dose; compounded tirzepatide availability depends on the current regulatory status. Check the compounding status page and discuss current availability with your telehealth provider.